Immunotherapy under NICE TA818
Nivolumab and ipilimumab first-line for unresectable pleural mesothelioma.
Sections are written to the same editorial standard as the drafted chapters and reviewed by named clinical, legal and lived-experience contributors before publication. See the editorial brief in the production plan for the voice and structure these sections will follow.